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Phospholipases A2 (PLA2) catalyze the hydrolysis of membrane 
phospholipids to produce free fatty acids and lysophospholipids, which have 
important functions in cell signaling. To date, however, little is known about 
differential expression and physiological functions of PLA2 isoforms in specific 
brain regions. The present study was carried out to determine differential 
expression of PLA2 isoforms in the prefrontal cortex (PFC) of the rat brain. Real 
time RT-PCR results indicated that sPLA2-XIIA had greater mRNA expression 
than iPLA2-VI or cPLA2-IVA in all brain regions, or compared to other sPLA2 
isoforms, in the PFC and hippocampus. Western blots showed a 24kDa band in 
different regions of the adult brain, and high levels of sPLA2-XIIA protein 
expression were detected in the PFC, striatum and thalamus. The enzyme was 
immunolocalized to neurons, and electron microscopy showed that sPLA2-XIIA is 
present in axon pre-terminals or growth cones that did not form synaptic contacts 
with dendrites. Injection of antisense oligonucleotide to sPLA2-XIIA in the PFC 
resulted in increases in phospholipid but decreases in lysophospholipid 
molecular species, consistent with decreased catalytic activity of the enzyme, 
and alterations in sphingolipids. sPLA2-XIIA knockdown also resulted in shorter 
latency timings in the passive avoidance test, and higher number of errors in the 
attention set-shifting task, indicating deficits in working memory and attention, 
respectively. Together the results show an important role of sPLA2-XIIA in lipid 






of opposing neural cell membranes to facilitate axon pathfinding and neural 
plasticity in the brain. 
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Figure 1.0. Sites of action of different 
PLA2 cleaves at the sn-2 position releasing arachidonic acid, PLC cleaves before the phosphate 
releasing diacylglycerol and PLD cleaves after the phosphate group releasing phosphatidic acid 
and alcohol as its products.
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The structural diversities between these classes of PLA2 indicate that its 
involvement in various biochemical processes and plays functional roles in both 
physiological and pathological conditions. The functionalities of each PLA2 class 
is dependent on its pathway of activation and cellular localization (Zhu et al., 
1996). The main metabolite, arachidonic acid (AA), can be modified into 
eicosanoids via the action of cyclooxygenases, thereby releasing inflammatory 
regulators such as prostaglandins and leukotrienes (Dennis, 1994). On the other 
hand, phospholipids including phosphatiylcholine (PC), 
phosphatidylethanolamine (PE), phosphatidylinositol (PI) and phosphatidylserine 
(PS) are hydrolyzed into its respective lysophospholipid species (Farooqui et al., 
2000a). These lysophospholipids are transient metabolic intermediates produced 
during membrane remodeling (Farooqui et al., 2000b). Lysophospholipids form 
micelles when present at low concentrations and tends to aggregate into 
cylindrical hexagonal phases at higher concentrations. Such aggregations are 
thought to alter membrane structures and ion-gated channels (Lundbaek and 
Andersen, 1994) by forming dimeric open channels. Therefore, regulation of 
PLA2 action is important to maintain basal levels of AA and 
lysoglycerophospholipids for normal brain function. In normal circumstances, 
fatty acids would be recycled by a deacylation/reacylation pathway to maintain its 
concentration in cells (Farooqui et al., 2000b). However under pathological 
conditions, a highly active PLA2 has been reported to cause the loss of neural 
glycerophospholipids, thereby affecting membrane fluidity and permeability. In 
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addition, the accumulation of lipid peroxides and free radicals may lead to the 
onset of neurodegenerative diseases (Farooqui and Horrocks, 1994). 
 
1.1 Cytosolic Phospholipase A2 
 The intracellular cPLA2 family has a typical molecular weight of 85 kDa 
that is characterized by its C2 domain at the N-terminal region. It is found highly 
expressed in the central nervous system (CNS) with the hindbrain showing high 
cPLA2 activity (Ong et al., 1999). Similarly, abundant expression of cPLA2 mRNA 
was also observed in most brain regions, with high expression in the pineal gland 
and pons (Kishimoto et al., 1999). Three paralogs of cPLA2 - cPLA2-α (Mr = 85 
kDa), cPLA2-β (Mr = 114 kDa) and cPLA2-γ (Mr = 61 kDa) are present in the brain 
and non neural tissues. cPLA2-α is pre-dominantly localized in the astrocytes 
(Stephenson et al., 1994) and post-synaptic dendrites to unlabeled axon 
terminals (Ong et al., 1999). The enzyme has high binding affinity to AA at the 
sn-2 position and does not require Ca2+ for catalysis although submicromolar 
Ca2+ is required for its translocation from the cytosol to membrane for binding 
purposes (Kramer and Sharp, 1997). Catalysis of glycerophospholipid is then 
facilitated by the C-terminus region of cPLA2-α mRNA which contains both the 
phosphorylation and catalytic sites. On the contrary, cPLA2-β and cPLA2-γ are 
more likely to target fatty acids at the sn-1 position (Song et al., 1999) and 
function at a lower rate than cPLA2-α. However, as compared to cPLA2-α, 
relatively little is known about the functions of cPLA2-β and cPLA2-γ till date. 
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Thus, the differential targets of cPLA2 serve to ensure that AA is released 
efficiency during receptor activation and signal transduction processes. 
 
1.2 Calcium Independent Phospholipase A2 
 The iPLA2 family is a Ca2+-independent phospholipase that has a typical 
molecular weight of 80 kDa. Two distinct members of iPLA2 includes iPLA2-VIA 
and iPLA2-VIB. iPLA2-VIA is conserved with iPLA2-VIB at the C-terminus but 
shares little homology at the N-terminus region. Different iPLA2 isoforms that 
have specific tissue localization and functions are generated via alternative 
splicing (Larsson et al., 1998). iPLA2-VI is the highest expressing PLA2 isoform in 
the brain (Molloy et al., 1998; Yang et al., 1999b; Yang et al., 1999a) and its 
protein expression decreases during aging (Aid and Bosetti, 2007). It is present 
in all brain regions, with high expression found in rat’s striatum, hypothalamus 
and hippocampus (Molloy et al., 1998). In the monkey brain, iPLA2 
immunolabeling was generally observed in the telencephalon including the 
cerebral cortex, septum, amygdala and striatum while the diencephalon which 
includes the thalamus, hypothalamus and subthalamic nucleus are lightly stained 
(Ong et al., 2005). At electron microscopy, immunoreactivity was observed in the 
neuronal nuclei and axon terminals. iPLA2 activity could be investigated via the 
use of a specific inhibitor, bromoenol lactone (BEL) (Ackermann et al., 1995). 
However, it is difficult to determine the specific role of iPLA2 in 
glycerophospholipid metabolism as BEL also acts on and inhibits other enzymes 
such as phosphatidate phosphohydrolase (Fuentes et al., 2003). It was found 
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that iPLA2 play significant functions in long-term potentiation (LTP), long-term 
depression (LTD), neural cell proliferation, apoptosis and differentiation (Akiba 
and Sato, 2004; Farooqui et al., 2004). 
 
1.3 Secretory Phospholipase A2 
Ten different isoforms of sPLA2 (IB, IIA, IIC, IID, IIE, IIF, III, V, X and XII), 
with molecular sizes ranging from 14-19kDa, had been identified in the brain. The 
isoforms are highly conserved with a Ca2+ binding loop (XCGXGG) and catalytic 
site (DXCCXXHD) domain (Titsworth et al., 2008). Stability of the enzymes is 
maintained by 6 disulfide bonds and 2 additional unique disulfide bonds which 
are suggested to protect them from thermal and chemical denaturation 
(Schulenburg et al., 2010). sPLA2 can be further divided into three major 
subgroups – conventional I/II/V/X sPLA2 and, atypical group III and XII sPLA2 
(Figure 1.3.1) (Murakami et al., 2010). Genes encoding for sPLA2-IIA, -IIC, -IID, -
IIE, -IIF and –V occupy the same chromosome locus and are therefore referred 
collectively as group II subfamily sPLA2 (Valentin et al., 2000). The atypical 
sPLA2-III and sPLA2-XIIA/XIIB possess poor homology against the conventional 
I/II/V/X sPLA2 with the exception of the Ca2+ binding domain and catalytic site 
(Figure 1.3.2) (Murakami et al., 2011). Each sPLA2 has its unique enzymatic 
properties and localization suggesting distinct pathophysiological roles in 
mammalian system (Lambeau and Gelb, 2008). Activation of substrate hydrolysis 
occurs via hydrogen bonding of water molecules to the histidine active site. 
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Figure 1.3.1. Sequence identity dedrogram of mouse and human sPLA2 that was aligned using 
ClustalW and dendrogram generated with Treeview. Dendrogram shows three major groups of 
sPLA2 – Group I/II/V/X sPLA2, Group III sPLA2 and Group XII sPLA2 [Adapted from (Murakami 
et al., 2010)] 
Figure 1.3.2. Schematic structure of mammalian sPLA2 isoforms. All sPLA2 have conserved 
Ca2+ binding loops and catalytic site, with the exception of sPLA2-XIIB that has a mutation in 
the catalytic site. sPLA2-III has an unique N- and C- terminus domain that appears to be 
removed in vivo [Adapted from (Murakami et al., 2010)] 
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The interaction is facilitated by a ligand cage that comprises an adjacent 
aspartate residue and Ca2+ binding loop (Masuda et al., 2005a).  
sPLA2 enzymes are able to exert its functions via several different 
mechanisms. Firstly, sPLA2 possess a secretory signal that requires high 
concentration of Ca2+ to carry out secretion in cells (Murakami et al., 2010). Thus, 
the primary target of sPLA2 is postulated to reside in extracellular spaces. 
Studies have proven that the enzyme is indeed versatile and able to interact with 
numerous targets in extracellular spaces. Secondly, sPLA2 can also act on 
phospholipids of intracellular vesicles, exosomes, lipoproteins and foreign 
microbial membranes (Fourcade et al., 1995; Hanasaki et al., 2002). Lastly, 
sPLA2 may also exhibit their functions via receptors or its binding partners that is 
independent of its enzymatic properties (Lambeau and Lazdunski, 1999; 
Pungercar and Krizaj, 2007).  
The physiological and pathological functions of sPLA2 have been 
investigated and identified using gene-manipulated mice (Table 1.3). Transgenic 
overexpression and knockout models of sPLA2 in tissues can provide informative 
hints and evidences for its potential functions in vivo based on their differential 
expression locations. Till date, only a few sPLA2 isoforms have been well studied 
while distinct information are still missing for other isoforms including sPLA2-IIC, 
sPLA2-IID, sPLA2IIE, sPLA2-IIF, sPLA2-XIIA and sPLA2-XIIB. Therefore, given 
sPLA2 significance in lipid metabolism in cells, the analysis of all sPLA2 isoforms 
should provide answers regarding the biological functions of each individual 
sPLA2. 
Section II 





Table 1.3: Phenotypes of transgenic and knockout mice  
sPLA2 Isoform Phenotypes in Tg mice Phenotype of knockout 
mice 
IB Unknown Reduction in phospholipid 
digestion in dietary tract 
IIA Diet induced atherosclerosis 
Protection from bacterial 




III Diet induced atherosclerosis 
Systemic inflammation 
Unknown 
V Lung dysfunction Reduced eicosanoid 
production 
Protection for Candida 
albicans infection 
Reduced LPS-induced lung 
injury 
X Lung defect 
Decrease lipoproteins 
Reduced allergen induced 
asthma 
Reduced myocardial injury 
 
1.3.1 sPLA2-IB 
 sPLA2-IB is a pancreatic-type PLA2 that has an unique loop of five amino 
acids and a group I specific disulfide bond between Cys11 and Cys77 (Seilhamer 
et al., 1986). It is synthesized in the pancreatic acinar cells as a zymogen with 
the N-terminal peptide trypsin cleaved in the duodenum to yield an active 
enzyme. The enzyme binds more tightly to anionic phospholipids than PC in the 
duodenum. However, the activity of sPLA2-IB can be greatly stimulated in 
conditions of lower concentrations of deoxycholate (Verheij et al., 1981), similar 
to the condition in the intestinal tract where bile acids are present. The sPLA2-IB-/- 
mice displayed resistance to obesity when fed with high fat or carbohydrate diet 
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(Huggins et al., 2002) due to the reduction of dietary and biliary PC and 
increased sensitivity towards insulin (Labonte et al., 2006). The efficacy of oral 
inhibitors on sPLA2-IB (Hui et al., 2009) suggest that sPLA2-IB inhibition may be 
a potential therapeutic strategy for diet-induced obesity and diabetes. Besides 
the pancreas, sPLA2-IB is also found highly expressed in the stomach and 
present at low levels in the spleen, lungs, colon, liver and eyes (Valentin et al., 
1999; Mandal et al., 2001; Kolko et al., 2007) 
 
1.3.2 sPLA2-IIA 
 sPLA2-IIA is known as an inflammatory-type sPLA2 that has a specific 
disulfide bond between Cys50 and the ending cysteine of the group II specific C-
terminus extension peptide (Kramer et al., 1989). sPLA2-IIA level of expression 
has been shown to be positively correlated to the severity of inflammatory 
diseases and injuries (Pruzanski and Vadas, 1991). The enzyme can act through 
heparin sulfate proteoglycan (HSPGs)-dependent and –independent fashion 
(Koduri et al., 1998; Murakami et al., 1998; Murakami et al., 2001). In the HSPG-
dependent mechanism of action, sPLA2-IIA binds to the anionic HSPG and 
internalized into the intracellular vesicular compartments of activated cells via the 
caveolae-dependent endocytotic pathway (Mounier et al., 2004).  
 sPLA2-IIA has been postulated to be involved in inflammation due to its 
proinflammatory stimuli-inducibility and AA releasing potential, as reported in a 
model of inflammatory arthritis (Boilard et al., 2010). However, sPLA2-IIA 
overexpression alone is insufficient in triggering inflammation, with corresponding 
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data pointing to the requirement of appropriate proinflammatory stimuli. In 
addition, sPLA2-IIA knockout mice are also found to be more susceptible to 
colorectal tumorigenesis, suggesting sPLA2-IIA function in tumour prevention 
(MacPhee et al., 1995). The most important function of sPLA2-IIA is perhaps its 
ability in antibacterial activity, mediated by its potency against the bacterial 
membranes (Nevalainen et al., 2008) that is rich in PE and phosphatidylglycerol 
(PG) (Singer et al., 2002). The enzyme is able to effectively exterminate gram-
positive and gram-negative bacteria in vitro in the rank order of sPLA2-IIA > -X > -
V > -XIIA > -IIE > -IB and IIF.  
 
1.3.3 sPLA2-IIC 
 sPLA2-IIC is a lipase with an additional disulfide bond between Cys87 and 
Cys93 in an extended loop region (Chen et al., 1994a). The enzyme is highly 
expressed in the spermatogenia of the mouse and rat testis (Masuda et al., 2004) 
while it codes for a non-functional protein in human due to a partial deletion in 
exon 3 (Tischfield et al., 1996).  
 
1.3.4 sPLA2-IID 
 sPLA2-IID is an enzyme that is most similar to sPLA2-IIA, but display lower 
substrate activity as compared to sPLA2-IIA (Singer et al., 2002). Expression of 
the enzyme was detected in the thymus and other lymphoid organs such as 
spleen and lymph nodes (Shakhov et al., 2000). sPLA2-IID suppresses the 
proliferation of CD4+ and CD8+ and inhibit the development of colitis and multiple 
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sclerosis in an enzymatic independent fashion, suggesting its 
immunosuppressive functions (von Allmen et al., 2009)  
 
1.3.5 sPLA2-IIE 
 sPLA2-IIE has low levels of expression in several tissues, with the uterus 
exhibiting highest expression amongst all tissues (Valentin et al., 1999). Its 
intrinsic enzymatic activity is also lower than sPLA2-IIA under standard assay 
conditions (Singer et al., 2002). sPLA2-IIE has a preference of hydrolyzing PG as 
compared to PE (Suzuki et al., 2000) and is abundantly found in the 
hippocampus and cerebral cortex (Kolko et al., 2006). Similar to sPLA2-IIA, 
sPLA2-IIE is also activated by pro-inflammatory stimuli, resulting in AA release 
and the generation of eicosanoid (Sun et al., 2010) 
 
1.3.6 sPLA2-IIF 
 sPLA2-IIF is an enzyme with a unique C-terminal extension of 30 amino 
acids which is composed of an odd cysteine and several prolines (Valentin et al., 
2000b). This cysteine might facilitate the formation of a homodimer or 
heterodimer with another protein. sPLA2-IIF is able to hydrolyze 
glycerophospholipids and release AA with potency similar to sPLA2-III (Murakami 
et al., 2002). The stability of the enzyme can be enhanced by N-glycosylation at 
three amino acid sites (Murakami et al., 2010). sPLA2-IIF has a strong enzymatic 
activity on anionic and zwitterionic phospholipids (Singer et al., 2002), thereby 
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allowing it to penetrate tightly packed monolayer and bilayer membrane 
phospholipids (Wijewickrama et al., 2006). 
 
1.3.7 sPLA2-III 
 sPLA2-III is an unique enzyme in the sPLA2 family as it possess an extra N 
and C-terminus, making it an unusually large 55 kDa protein that is composed of 
three distinct domains (Valentin et al., 2000a). The central domain shares certain 
characteristics with the bee venom group III sPLA2, including 10 cysteine 
residues, Ca2+ loop and catalytic site. However, the human sPLA2-III only shares 
31% homology with the bee venom sPLA2-III, suggesting distinct biochemical 
properties between the two different isoforms. Only the central domain that is 
devoid of its N and C domains is required for catalytic functions. Overexpression 
of sPLA2-III in cells resulted in AA secretion that is even higher as compared to 
sPLA2-IIA, but similar to sPLA2-V and sPLA2-X (Murakami et al., 2003; Murakami 
et al., 2005). sPLA2-III mRNA is generally expressed in the heart, kidney and liver 
(Valentin et al., 2000a) while immunolabelling is detected in vascular 
endothelium, central nervous system and male reproductive tracts (Murakami et 
al., 2005). High amount of enzyme is specifically found in the dorsal root ganglion 
neurons in mice and function to facilitate neuronal outgrowth via the production of 
LysoPC. Mass spectroscopy reveals that PS is the preferred substrate molecule 
of sPLA2-III which suggest that the enzyme is linked to systemic inflammation by 
cleaving PS that is exposed on activated or apoptotic inflammatory cells 
(Murakami et al., 2010). 
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 sPLA2-V is a basic enzyme and it does not possess any sPLA2-I or sPLA2-
II specific disulfide bonds or sPLA2-II specific C-terminal extension (Chen et al., 
1994b). sPLA2-V mRNA has been detected in the heart and skin. High level of 
expression is found in the rat and mouse brains, specifically in the neurons of the 
cortex and hippocampus (Molloy et al., 1998). Immunolabelling was also 
detected in the rat cerebellum (Shirai and Ito, 2004) 
Similar to sPLA2-IIA, sPLA2-V can function via the HSPG-dependent or –
independent mechanism. sPLA2-V has a high affinity for HSPG and are therefore 
rather dependent on the HSPG-shuttling pathway (Murakami et al., 1999; 
Murakami et al., 2001). The enzyme has a preference to release unsaturated 
fatty acids e.g. palmitic, oleic and linoleic acids from cellular membranes, 
lipoproteins and phospholipid vesicles (Chen and Dennis, 1998; Pruzanski et al., 
2005). sPLA2-V is present in the golgi apparatus and endosomes, ready to ingest 
materials that is recruited to the phagosome (Balestrieri et al., 2006). This might 
contribute to sPLA2-V’s ability to kill fungi and its protection against the infectious 
environment through an innate immune response mediated phagocytotic and 
phagolysosome fusion mechanisms. sPLA2-V preference for unsaturated fatty 
acids like oleic acid-PC in fungal membrane could substantiate its high efficacy 
against fungi as compared to bacteria. The LPC released from oleic acid-PC 










 sPLA2-X is a phospholipase that has both structural features of sPLA2-I 
and sPLA2-II including the group I and II specific disulfides (Cupillard et al., 1997) 
bonds, group I specific propeptide and group II specific C-terminal extension. 
Similar to sPLA2-IB, sPLA2-X is synthesized as a zymogen and the removal of 
the propeptide by proteases is essential to produce a mature sPLA2-X for 
enzymatic action (Morioka et al., 2000). However, the mechanism of action for its 
proteolytic propeptide cleavage is still not well understood. Secretion of sPLA2-X 
to its targeted substrate molecules could be facilitated by post translational 
modification such as N-glycosylation (Masuda et al., 2005b). The enzyme is 
equally active on zwitterionic and anionic phospholipids (Pan et al., 2002). 
sPLA2-X has the highest binding affinity to PC which made it the most potent 
sPLA2 isoform that is able to release free AA from plasma membrane (Murakami 
et al., 1999). Therefore, the dysfunction in controlling sPLA2-X expression could 
lead to serious implications in in vivo pathological conditions. sPLA2-X is found 
transcribed in neurons and exhibit neuritogenic functions via the production of 
LPC (Ikeno et al., 2005). 
 
1.3.10    sPLA2-XIIA 
   The atypical sPLA2-XIIA is a 21 kDa enzyme that retains the histidine 
and aspartate catalytic dyad found in other sPLA2 isoforms (Muñoz-Sanjuán and 
Brivanlou, 2005). A full length sPLA2-XIIA protein constitutes an upstream signal 
peptide, Ca2+ binding loop and downstream active site (Figure 1.3.10). However, 
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remains unknown with studies indicating low catalytic activities in cells using 
standard assay conditions (Murakami et al., 2003). Thus, It is postulated that 
sPLA2-XIIA is incapable of liberating AA due to its weak catalytic activity, 
although there is a possibility of it affecting AA metabolism at high gene 
expression levels (Murakami et al., 2003). As such, the catalytic activity of sPLA2-
XIIA may not be crucial for its cellular functions. Ironically, sPLA2-XIIA still holds 
the ability to kill gram-negative bacteria such as E. Coli and Helicobacter pylori 
(Koduri et al., 2002; Huhtinen et al., 2006) and performed the task more 
efficiently than sPLA2-IIA. Further, sPLA2-XIIA is postulated to play significant 
functions during the early development of Xenopus laevis (Muñoz-Sanjuán and 
Brivanlou, 2005). sPLA2-XIIA gain of function in X. laevis embryos results in 
ectopic neurogenesis of the  olfactory sensory structures that includes olfactory 
bulb and sensory epithelia. The data put sPLA2-XIIA as the only protein that is 
capable of inducing anterior sensory neural structures during vertebrate 
development. 
 
1.3.11    sPLA2-XIIB 
    sPLA2-XIIB is the only sPLA2 enzyme that is catalytically inactive due to 
the presence of a point mutation (histidine to leucine) in the active site (Rouault 
et al., 2003). The enzyme is highly conserved with mouse and human sPLA2-
XIIA, showing 94% sequence identity. sPLA2-XIIB is highly expressed in the liver 
and small intestine and may be differentially expressed during tumorigenesis 
(Rouault et al., 2003). 
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1.4 PLA2 Function in the Brain 
 The brain is an intricate organ that requires high level of homeostatic 
balance to maintain its proper functions. As described above, each of the PLA2 
isoforms performs its specific function, based either on its structural feature, 
tissue localization or substrate preference. Therefore, the PLA2 family is 
considered to hold housekeeping functions as well as other cellular biochemical 
roles. The housekeeping functions generally encompass their roles in 
glycerophospholipids turnover which is important during neuronal membrane 
remodeling. In normal circumstances, PLA2 is also significant in the removal of 
peroxidized fatty acids in the brain, which could cause serious complications as 
reactive oxygen species (ROS), if allowed to remain in the brain. In conditions 
where the rate of PLA2-mediated hydrolysis of membrane is greater than 
membrane repair, the accumulation of free fatty acids would result in the loss of 
membrane integrity and its corresponding cellular functions (Farooqui and 
Horrocks, 1991). Therefore, tight regulation of PLA2 expression is critical to cell 
and neuronal survival in the brain. In addition, the downstream metabolites of 
PLA2 could also act as secondary messengers that are involved in the 
modulation of neurotransmitter release, long-term potentiation, membrane repair, 











1.4.1 Neurotransmitter Release 
 The basis of neuron-to-neuron or neuro-to-muscle communication relies 
heavily on the release of neurotransmitters from synaptic vesicles in the axon 
terminals into the synaptic clefts (Rohrbough and Broadie, 2005). The synaptic 
vesicles act as storage space for neurotransmitters like glutamate, acetylcholine, 
dopamine and norepinephrine. During signal transduction, the movement of 
calcium ions into the axon terminals induces the docking of neurotransmitter filled 
vesicles onto the pre-synaptic membrane, where fusion of vesicles and pre-
synaptic membrane results in the exocytotic motion of neurotransmitter into the 
synaptic cleft (Li and Chin, 2003). Thereafter, these neurotransmitters will diffuse 
across the synaptic cleft and activate their respective receptors found on the 
post-synaptic membrane. Although the exact molecular mechanism of 
neurotransmission is still unknown, the movement and dependence on calcium 
ions via the voltage-gated ion channels might induce the activation of cPLA2 
(Moskowitz et al., 1982; Bloch-Shilderman et al., 2002). This correlates to the 
findings that PLA2 inhibitors are able to suppress and block exocytosis of 
neurotransmitters in the rat brain and PC12 cell cultures (Matsuzawa et al., 1996; 
Abu-Raya et al., 1998; Bloch-Shilderman et al., 2002; Wei et al., 2003). In 
addition, the downstream metabolite of PLA2, AA, is involved in the translocation 
of Protein Kinase C (PKC), which play roles in neurotransmission (Bramham et 
al., 1994). It is postulated that PLA2 act by disrupting the membrane integrity of 
synaptic vesicles in a calcium-dependent manner and thus, enabling the release 
of neurotransmitters into the synaptic cleft (O'Regan et al., 1996).    
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1.4.2 Long-Term Potentiation 
 The induction of learning and memory is governed by two molecular 
processes - long-term potentiation (LTP) and long-term depression (LTD) (Bliss 
and Collingridge, 1993; Chen and Tonegawa, 1997). Both processes are 
dependent on the basis of synaptic plasticity and remodeling that results in the 
association or dissociation of synaptic connections between neurons.  
LTP is triggered by calcium ions entry into the post-synaptic membrane 
via NMDA receptors, with the connection between neurons maintained by pre-
synaptic mechanisms. The activation of PLA2 during neurotransmission results in 
the release of AA in the post-synaptic membrane. Released AA would then 
diffuse back across the synaptic cleft to act on the pre-synaptic terminals as 
retrograde neurotransmitters and activates PKC (Williams et al., 1989). Together, 
the activation of both PKC and PLA2 in the pre-synaptic terminals plays 
significant roles in the induction and maintenance of LTP (Bernard et al., 1994). 
In addition, studies performed using iPLA2 specific inhibitor BEL just before 
tetanic stimulation display the obvious lack of LTP induction (Wolf et al., 1995). 
The modulation of LTP is likely to occur via two glutaminergic receptors - the 
NMDA and AMPA receptors.   
On the contrary, the induction of LTD occurs during a low but prolong 
stimulation of a synapse coupled with NMDA receptor mediated Ca2+ ion influx. 
Studies utilizing iPLA2 inhibitors on hippocampal slice cultures show that the 
formation of LTD is blocked (Okada et al., 1989). In addition, treatment of these 
slice cultures with AA mimics the formation of LTD (Massicotte, 2000). The 
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phosphorylation of GluR2 receptors at Ser880 by protein kinase A is shown to 
mediate receptor internalization and thus modulate synaptic transmission (Chung 
et al., 2003; Seidenman et al., 2003). Together, these results suggest significant 
roles of PLA2 in the induction of LTD. 
 
1.4.3 Membrane Repair 
 The neuronal membrane is composed primarily of glycerophospholipid 
species. Its abundance in the brain makes it more susceptible to the attack by 
reactive oxygen species in the brain, forming hydroperoxides, peroxidized 
glycerophospholipids and degraded products in the process (Farooqui et al., 
2000a). The structural changes caused by peroxidized glycerophospholipids in 
the membrane induce a packing defect and exposes the sn-2 ester bond that 
makes it more accessible for PLA2 action. It was also found that peroxidized 
glycerophospholipid is the preferred substrate molecule of PLA2 due to its 
structural features (McLean et al., 1993). Thus, removal of these peroxidized 
fatty acyl chains allows for membrane repair and restores the appropriate 
physiochemical states of the membrane and prevent peroxidative cross linking 
reactions. Without such homeostatic processes, the accumulation of peroxidized 











1.4.4 Neurite Outgrowth and Neuritogenesis 
 AA, the downstream metabolite of PLA2 isoforms, plays significant function 
in neurite outgrowth, regeneration and growth signal transduction processes 
(Suburo and Cei de Job, 1986). Cells that were treated with PLA2 inhibitor, NG 
108-15, shows impair neurite outgrowth (Smalheiser et al., 1996) while PLA2 
activators like melittin promotes neurite outgrowth, indicating that PLA2 and its 
downstream metabolites is generally involved in neurite outgrowth. However, the 
exact mechanism of how AA is able to induce neurite outgrowth is still unknown 
although studies have shown that PKC action might play significant role in 
neurite outgrowth (Katsuki and Okuda, 1995).  
 Several sPLA2 isoforms have been shown to induce neurite outgrowth in 
vitro. The action of sPLA2 on PC generates lysoPC which then induces G-
protein-coupled receptor (GPCR) secondary messenger signaling pathways 
(Ikeno et al., 2005; Masuda et al., 2005b). It is postulated that lysoPC will 
activate L-type calcium channels, PKC and mitogen-activated protein kinase 
(MAPK). The influx of Ca2+ ions may also trigger various cellular processes that 
lead to neuritogenesis via the actions of calcium-binding proteins and adhesion 
molecules (Doherty et al., 1991; Gomez and Spitzer, 2000). sPLA2-IIA, sPLA2-III 
and sPLA2-X have been shown to induce neuritogenesis via its active site. The 
induction of nerve growth factor by sPLA2 isoforms is also significant as studies 
have shown that inhibition of sPLA2 activity by anti-sPLA2 antibody and siRNA 
results in the attenuation of neuritogenesis (Masuda et al., 2005b), indicating that 
sPLA2 plays an important role in neuritogenesis. 
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1.4.5 Inflammatory and Anti-Inflammatory Processes 
 Inflammation occurs in tissue organs as a means of protection against 
infections by foreign agents, and preventing their detrimental effects by restoring 
physiological conditions. Although inflammation functions as a protective 
procedure, excess and prolong onset could instead lead to tissue damage 
(Correale and Villa, 2004). In the brain, inflammation is initiated in the astrocytes 
and microglia cells. The activation of microglia cells during inflammation would 
stimulate the release of proinflammatory cytokines such as interleukin-1 and 
tumour necrosis factor-α. Presence of these cytokines and growth factors 
controls the generation of AA by PLA2, formation of proinflammatory eicosanoids 
by cyclooxygenase and the release of platelet-activating factor (PAF) by PLA2 
and acetyltransferase (Bazan, 2003). These eicosanoids and PAF would then 
bind to their respective receptors, affecting membrane lipid packing and 
asymmetry which in turn lead to activation of sPLA2 (Serhan, 2004). The 
activation of sPLA2 would then initiate the synthesis of prostaglandins, a 
molecule that would initiate inflammatory responses. All the above mentioned 
metabolites serve to either induce or maintain the inflammatory process.    
 
1.4.6 Neurodegeneration 
 Neurodegeneration is a process where the death of neurons, astrocytes 
and oligodendrocytes occur in the CNS. The two common mechanism of action 
includes necrosis and apoptosis. The occurrence of necrosis is passive and 
characterized by cell swelling, changes in membrane fluidity, increase calcium 
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ion influx and disruption of ion homeostasis, leading to membrane lysis and 
spillage of intracellular contents that will result in an inflammatory reaction (Majno 
and Joris, 1995). On the contrary, apoptosis is an active process that is initiated 
by caspases. Caspases are a family of endoproteases that targets aspartate 
residues in protein molecules. Its target molecules include secondary messenger 
molecules such as PKC, cPLA2, iPLA2, and cytoskeletal proteins like actin and 
Bcl-2 family of apoptotic-related proteins (Sastry and Rao, 2000). The process of 
apoptosis is characterized by cell shrinkage, chromatin condensation, increased 
intracellular calcium ions, changes in membrane fluidity and generation of 
mitochondrial oxyradical (Sastry and Rao, 2000). 
 
1.5 Arachidonic Acid in the Brain 
 The neuronal membrane is composed mainly of glycerophospholipids that 
undergoes alterations during neuronal death and membrane remodeling. 
Glycerophospholipids can be recycled via a rapid deacylation-reacylation 
process that is mediated by PLA2 and an acyltransferase (Sun and MacQuarrie, 
1989; Farooqui et al., 2000b). The process is also important in governing the 
introduction of polyunsaturated fatty acids into glycerophospholipids.  
 AA and docosahexanoic acid (DHA) are the two most abundant 
polyunsaturated acids present in the brain. AA is present in various areas of the 
brain ranging from the white matter to the grey matter. On the contrary, DHA is 
found mostly in neuronal and synaptic membranes. The presence of AA and 
DHA is extremely important in the brain as they are also precursors of 
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eicosanoids and docosanoids respectively, molecules that are critical in inducing 
cell signaling (Farooqui and Horrocks, 2006).  
 The release of AA is mediated by two enzymatic mechanisms – direct 
mechanism involving PLA2 and an indirect mechanism involving PLC 
diacylglycerol lipase pathway (Farooqui et al., 1989). The presence of AA in the 
brain is of physiological significance since it mediates both LTP and LTD (Das, 
2003). In addition, AA is also shown to modulate ion channels, neurotransmitter 
release and neuronal cell differentiation (Farooqui et al., 2000a). AA may also 
regulate neurotransmission as retrograde neurotransmitter in glutaminergic 
neurons (Williams et al., 1989). These messengers are able to cross the synapse 
by diffusion and exert effects in the pre-synaptic axon terminals, resulting in 
sustained generation of action potential during LTP (Bliss et al., 1986; Bekkers 
and Stevens, 1990; Malinow and Tsien, 1990). Lastly, AA also stimulates uptake 
of glucose in the cerebral cortex which is critical in providing energy and 
maintaining ATP metabolism in the brain. 
 Under pathological conditions, the accumulation of AA has detrimental 
effects on neuronal cell membrane integrity. It causes intracellular acidosis and 
uncouples oxidative phosphorylation (Schapira, 1996), a process that is 
important for the production of ATP in the mitochondria. As a result, the 
mitochondrial swelling induces alterations in membrane fluidity and ion 
movements (Farooqui et al., 1997). Besides that, AA also leads to retention and 
accumulation of glutamate in the synaptic cleft by down regulating glutamate 
transporters in the brain (Toborek et al., 1999).  
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1.6 PLA2 receptors 
 sPLA2s have been found mostly in snake and bee venoms (Kini and 
Evans, 1989), where they share various conserved characteristics with the 
mammalian sPLA2 including its primary and tertiary structures (Davidson and 
Dennis, 1990; Dennis, 1994). The venoms play significant functions as 
neurotoxins, myotoxins, anticoagulants and proinflammatory proteins (Kini and 
Evans, 1989). The pathological effects of these venom sPLA2s have been 
attributed to its high binding affinity to sPLA2 specific receptors (Lambeau et al., 
1989; Lambeau et al., 1990; Lambeau et al., 1991b; Lambeau et al., 1991a; 
Lambeau et al., 1994). Two types of receptors have been identified for sPLA2 
binding – N (Neuronal)-type PLA2 receptor (Lambeau et al., 1989) and M 
(Muscle)-type PLA2 receptor (Lambeau et al., 1990; Lambeau et al., 1994) that 
are found in the brain and rabbit skeletal muscle respectively.  
The N-type receptors are also highly expressed in the heart, skeletal 
muscles, kidney, lungs, liver and pancreas (Lambeau et al., 1991a). It has 
distinct binding targets as compared to the M-type receptors, having high affinity 
for neurotoxic sPLA2 like OS2 and bvPLA2 but does not associate with pancreatic 
and inflammatory type sPLA2 (Lambeau et al., 1989). These receptors are 
predicted to mediate physiological, pathological and toxic effects of sPLA2. 
The M-type receptor is a 180 kDa protein and binds several venom sPLA2 
like OS1 and OS2, but does not bind bvPLA2.Unlike the N-type receptors, these 
receptors mainly associates with the pancreatic and inflammatory type sPLA2 
with high affinity, suggesting that sPLA2 are endogenous ligands of the M-type 
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receptors (Lambeau et al., 1994). Interaction studies between sPLA2 and M-type 
receptors showed that the Ca2+ binding loop of sPLA2 is critical for its binding of 
the M-type receptor (Lambeau et al., 1994). Although its physiological role is still 
unknown, it is postulated to be crucially involved in effecting the role of 
pancreatic sPLA2. 
 
1.7 Aims of the present study 
The above findings suggest an important role of members of the PLA2 
family in neuronal plasticity and / or signaling. To date, however, most studies on 
the functions of PLA2 have been carried out in vitro, and little is known about 
relative expression of PLA2 isoforms, or their physiological roles in specific 
regions of the brain and CNS. The present study was carried out in view of the 
importance of the importance of PLA2 and its products such as AA in cell 
signaling so as to determine the differential expression of PLA2 isoforms in 
different regions of the CNS, particularly in the prefrontal cortex (PFC) where 
high levels of sPLA2-XIIA mRNA and protein expression is observed. Localization 
of the sPLA2-XIIA isoform will also be determined using immunohistochemistry 
and electron microscopy. Finally, antisense oligonucleotide knockdown of sPLA2-
XIIA will be carried out to establish the role of sPLA2-XIIA in lipid metabolism and, 


























EXPRESSION PROFILE OF VARIOUS PLA2 ISOFORMS 










More than 10 sPLA2 isozymes have been identified in the mammalian 
brain (Titsworth et al., 2008), and high levels of sPLA2 enzymatic activity are 
present in the normal rat hippocampus, pons and medulla oblongata (Thwin et al., 
2003). sPLA2 activity is upregulated in multiple sclerosis (Cunningham et al., 
2006) and Alzheimer’s disease (Moses et al., 2006), suggesting a role in 
neuroinflammation and neurodegeneration. sPLA2-IIA (Ferrini et al., 2010), 
sPLA2-III (Masuda et al., 2008) and sPLA2-X (Masuda et al., 2005b) have been 
shown to facilitate neurite outgrowth. In addition, sPLA2-IIA was found to induce 
capacitance increases, indicating exocytosis in PC12 cells and cultured 
hippocampal neurons (Wei et al., 2003). sPLA2-IIA is packaged in secretory 
granules and secretion is facilitated by agonists of kainate receptors in a PKC 
dependent manner (Than et al., 2012). 
On the other hand, cPLA2 is involved in disease pathogenesis of multiple 
sclerosis  (Kalyvas and David, 2004), Alzheimer’s disease (Gentile et al., 2012), 
algesia (Lucas et al., 2005) and tumour progression (Linkous and Yazlovitskaya, 
2010). Immunohistochemical results show that dense cPLA2 immunolabelling is 
found in the hindbrain with light immunostaining observed in the forebrain and 
midbrain (Farooqui et al., 2000c). iPLA2 has been shown to be implicated in 
neurodegenerative diseases (Morgan et al., 2006), Barth syndrome (Malhotra et 
al., 2009), schizophrenia (Ross et al., 1997) and Alzheimer’s disease (Talbot et 
al., 2000). Immunohistochemical staining indicate expression of iPLA2 expression 
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in the olfactory bulb, hippocampus including CA1-3 fields, dentate gyrus and 
brainstem (Shirai and Ito, 2004) 
The significance of PLA2 in maintaining membrane lipid homeostasis of 
the brain is evident in all these studies. However, the expression profile of the 
various PLA2 isoforms in the brain cortical and hippocampal regions has not 
been elucidated till date. This study was therefore carried out to elucidate the 
mRNA expression levels of all PLA2 isoforms in the cortex and hippocampus 
which governs important brain functions such as cognition and memory. The 
highest expressing PLA2 isoform was then subjected to further mRNA expression 
studies in the CNS including the olfactory bulb, prefrontal cortex, striatum, 
hippocampus, thalamus/hypothalamus, cerebellum, brainstem, and spinal 
column (cervical, thoracic and lumbar). Western immunoblot was also carried out 
for the highest expressing PLA2 isoform to elucidate its protein expression in 









2.1.2  Materials and Methods 
2.1.2.1 Real-time Reverse Transcriptase Polymerase Chain Reaction  
(RT-PCR) 
Six adult male Wistar rats were used for this portion of the study. The rats 
were anesthetized with intraperitoneal injection of ketamine and xylazine cocktail 
(prepared with 7.5 ml ketamine (75 mg/kg), 5 ml xylazine (10 mg/kg), and 7.5 ml 
0.9% sodium chloride solution) and sacrificed by decapitation. The olfactory bulb, 
prefrontal cortex, striatum, thalamus/hypothalamus, hippocampus, cerebellum, 
brainstem and spinal cord (cervical, thoracic and lumbar) were quickly dissected 
out, immersed in RNAlater® solution (Ambion, TX, USA) and snap frozen in 
liquid nitrogen. Total RNA was extracted using TRizol reagent (Invitrogen, CA, 
USA) according to manufacturer's protocol. RNeasy® Mini Kit (Qiagen, Inc., CA, 
USA) was used to purify the RNA. Samples were reverse transcribed using High-
Capacity cDNA Reverse Transcription Kits (Applied Biosystems, CA, USA). 
Reaction conditions were 25 °C for 10 min, 37 °C for 120 min and 85 °C for 5 s. 
Real-time PCR amplification was performed using 7500 Real time PCR system 
(Applied Biosystems) on TaqMan® Universal PCR Master Mix (Applied 
Biosystems) and sPLA2-IB (Rn00580896_m1), sPLA2-IIA (Rn00580999_m1), 
sPLA2-IIC (Rn01520676_m1), sPLA2-IID (Rn01520520_m1), sPLA2-IIE 
(Rn01516481_m1), sPLA2-IIF (Rn01516171_m1), sPLA2-III (Rn01442985_m1), 
cPLA2-IVA (Rn00591916_m1), sPLA2-V (Rn00567782_m1), iPLA2-VI 
(Rn00588064_m1), sPLA2-X (Rn00691350_m1), sPLA2-XIIA (Rn01518649_m1), 
sPLA2-XIIB (Rn01433433_m1) and β-actin probes (Rn00667869_m1) (Applied 
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Biosystems, CA, USA) according to the manufacturer’s instructions. The PCR 
conditions were: incubation at 50 °C for 2 min and 95 °C for 10 min followed by 
40 cycles of 95 °C for 15 s and 60 °C for 1 min. All reactions were carried out in 
triplicates. The threshold cycle (CT) was measured as the number of cycles 
which the reporter fluorescence emission exceeds the preset threshold level. 
Amplified transcripts were quantified using the comparative CT method (Livak 
and Schmittgen, 2001), with the formula for relative fold change = 2–∆∆CT. The 
mean and standard error were then calculated.  
 
2.1.2.2 Western Blot Analyses 
Six Wistar rats at each time point, aged one day, two weeks and three 
postnatal weeks; and adult rats were used for this portion of the study. They were 
deeply anesthetized and sacrificed by decapitation. Various parts of the rat brain 
including olfactory bulb, prefrontal cortex, striatum, thalamus/hypothalamus, 
hippocampus, cerebellum, brainstem and spinal cord (cervical, thoracic and 
lumbar) were dissected out, and homogenized using a Tissue Tearor™ (Biospec, 
OK, USA) in 10 volumes of ice-cold buffer containing 0.32 M sucrose, 4 mM Tris-
Cl, pH 7.4, 1 mM EDTA, and 0.25 mM dithiothreitol. The homogenates were 
centrifuged at 13,000 g, and protein concentration in the supernatant determined 
using the BioRad protein assay kit (Bio-Rad Laboratories, CA, USA). Total 
proteins were resolved in 15% SDS polyacrylamide gels under reducing 
conditions and electrotransferred to a polyvinylidene difluoride (PVDF) 
membrane (Amersham Pharmacia Biotech, Little Chalfont, U.K.). Non-specific 
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binding sites on the PVDF membrane were blocked by incubation with 5% skim 
milk in 0.1% TBS-Tween for 1 hr. The PVDF membrane was incubated overnight 
with an affinity purified rabbit polyclonal antibody to sPLA2-XIIA, diluted 1:500 
dilution in 5% skim milk in 0.1% TBS-Tween at 4 °C. The antibody was raised 
against a region within amino acids 22 and 115 of the human sPLA2-XIIA (Novus 
Biologicals, CO, USA), which shares 95% homology with the rat sPLA2-XIIA. 
Peptide competition assay was carried out with 5X protein concentration of the 
above peptide antigen (synthesized by 1st Base, Singapore). The peptide was 
pre-incubated with antibody overnight before immunoblotting. Membrane was 
incubated with horseradish peroxidase conjugated anti-rabbit immunoglobulin 
IgG (ThermoFisher Scientific, MA, USA) for 1 hr at room temperature. The 
protein was visualized with an enhanced chemiluminescence kit (Pierce, 
Rockford, IL) according to the manufacturer’s instructions. Intensities of the 









2.1.3  Results 
2.1.3.1 Differential Expression of sPLA2-XIIA mRNA in the CNS 
 
Figure 2.1.3.1. Real-time RT-PCR analyses of sPLA2-XIIA, cPLA2-IVA and iPLA2-VI mRNA 
distribution in various parts of the rat brain including olfactory bulb (OB), prefrontal cortex (PFC), 
striatum (ST), thalamus/hypothalamus (TH), hippocampus (HC), cerebellum (CB), brainstem (BS), 
cervical spinal cord (SC(C)), thoracic spinal cord (SC(T)) and lumbar spinal cord (SC(L)). Values 
were normalized to the lowest expressing cPLA2-IVA in the hippocampus. Data represents the 
mean and standard error from 6 Wistar rats. sPLA2-XIIA was found highly expressed in the 
prefrontal cortex. 
 
Real time RT-PCR results indicated that sPLA2-XIIA had the highest 
expression level in all brain regions compared to other highly expressed PLA2 
isoforms, iPLA2-VI and cPLA2-IVA (Figure 2.1.3.1). The level of sPLA2-XIIA was 
highest in the prefrontal cortex, followed by the olfactory bulb, brainstem, 
cerebellum, cervical spinal cord, thalamus, thoracic spinal cord, lumbar spinal 
cord, hippocampus and striatum. Comparison across  cPLA2-IVA,  iPLA2-VIA and 






























prefrontal cortex, olfactory bulb and brainstem, while low level of expression were 
found in the hippocampus and striatum. 
 
2.1.3.2        Differential Expression of PLA2 Isoforms in the Prefrontal Cortex 
 
Figure 2.1.3.2. Real-time RT-PCR analyses of sPLA2, cPLA2, iPLA2 isoforms in the prefrontal 
cortex. Values were normalized to the lowest expressing sPLA2-X. Data represents the mean and 
standard error from 6 Wistar rats. sPLA2-XIIA was found to be the highest expressing PLA2 
isoform in the prefrontal cortex. 
 
Comparison between sPLA2 isoforms (-IB, -IIA, -IIC, -IID, -IIE, -IIF, -III, -V, 
-X, -XIIA, -XIIB) showed that sPLA2-XIIA was the highest expressing isoform in 
the prefrontal cortex followed by iPLA2-VIA (Figure 2.1.3.2). sPLA2-IB, sPLA2-IIC, 
sPLA2-IID, sPLA2-III, sPLA2-V and cPLA2-IVA had moderate expression levels 
while sPLA2-IIA, sPLA2-IIE, sPLA2-IIF, sPLA2-X and sPLA2-XIIB possessed low 



















Expression of PLA2 Isoforms in the Prefrontal Cortex
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2.1.3.3 Differential Expression of PLA2 Isoforms in the Hippocampus 
 
Figure 2.1.3.3. Real-time RT-PCR analyses of sPLA2, cPLA2, iPLA2 isoforms in the hippocampus. 
Values were normalized to the lowest expressing sPLA2-X. Data represents the mean and 
standard error from 6 Wistar rats. sPLA2-XIIA was found to be the highest expressing PLA2 
isoform in the hippocampus. 
 
Comparison between sPLA2 isoforms (-IB, -IIA, -IIC, -IID, -IIE, -IIF, -III, -V, 
-X, -XIIA, XIIB) showed that sPLA2-XIIA was the highest expressing isoform in 
the hippocampus followed by iPLA2-VIA (Figure 2.1.3.3). sPLA2-IIC, sPLA2-III, 
sPLA2-V, cPLA2-IVA had moderate expression levels while sPLA2-IB, sPLA2-IIA, 
sPLA2-IID, sPLA2-IIE, sPLA2-IIF, sPLA2-X and sPLA2-XIIB possessed low 
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Figure 2.1.3.4. (A) Immunoblot of 
the rat brain including olfactory bulb, prefrontal cortex, striatum, thalamus/hypothalamus, 
hippocampus, cerebellum, brainstem,
cord against sPLA2-XIIA antibody
loading of samples. Blots incubated with antigen absorbed antibody shows an absence of visible 
band at 24kDa. (B) Densitometric analysis of sPLA
β-actin. (C) Western Blot analyses of sPLA
of SHSY5Y cells, PC12 cells, 1 day, 2 weeks and 3 weeks 
observed in SH-SY5Y cells, PC12 cells and 1 day rat pup protein homogenates while
band was found in 2 weeks and 3 weeks rat pup protein homogenates.
 
The sPLA2-XIIA antibody detected a single 24 kDa ba
(Figure 2.1.3.4A). The 24 kDa band is consistent with a predicted 21 kDa sPLA
XIIA protein size that 
modifications could include
to occur with other PLA
was found to have the highest protein expression, followed by the striatum, 
thalamus, brainstem, cerebellum, cervical spinal cord, thoracic spinal cord, 
hippocampus, olfactory bulb and lumbar spinal cord. Quantitative densitometric 
C 
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total proteins resolved from adult Wistar rats in various parts of 
 cervical spinal cord, thoracic spinal cord and lumbar spinal 
. Protein levels of β-actin were also assayed to verify equal 
2-XIIA band intensity that were normalized to 
2-XIIA and β-actin expression in protein homogenates 
postnatal rat pups. A 18kDa band was 
 
nd in the adult rat brain 
has undergone post-translational modification. These 
 phosphorylation and glycosylation have been shown 




 a 24kDa 
2-
). The PFC 
Chapter 1 





of immunoblots showed similar sPLA2-XIIA expression pattern with high 
expression level in the PFC (Figure 2.1.3.4B). In neuroblastoma SH-SY5Y cells, 
pheochromocytoma PC12 cells and PFC homogenates from 1 day post-natal rat 
pups, an 18 kDa band was observed instead of the 24 kDa band (Figure 
2.1.3.4C). Blots that were incubated with sPLA2-XIIA immunizing peptide 










The present study was carried out to elucidate the expression levels of 
sPLA2-XIIA against other PLA2 isoforms and its expression pattern across 
different brain regions. Real time RT-PCR results indicate that sPLA2-XIIA mRNA 
is present in all brain regions (olfactory bulb, prefrontal cortex, striatum, 
thalamus/hypothalamus, hippocampus, cerebellum, brainstem and spinal cord) 
and had greater expression compared to iPLA2-VI and cPLA2-IVA. This isoform 
has a an N-terminus signal peptide, a Ca2+ binding loop and a C-terminus 
catalytic site (Gelb et al., 2000). sPLA2-XIIA was also identified as the highest 
expressing isoform among all PLA2s in the PFC followed by iPLA2-VIA, cPLA2-
IVA, sPLA2-IIC, sPLA2-III, sPLA2-IID, sPLA2-V, sPLA2-IB, sPLA2-IIA, sPLA2-IIF, 
sPLA2-XIIB, sPLA2-IIE and sPLA2-X. The second highest expressing isoform, 
iPLA2-VI showed similar expression pattern, with the PFC and olfactory bulb 
having the highest expression levels. Low expression level of sPLA2-IIA (Molloy 
et al., 1998) and high expression of sPLA2IB (Kolko et al., 2007) and sPLA2-V 
(Molloy et al., 1998) in the hippocampus are consistent with previous findings. 
Similarly, high expression of sPLA2IB (Kolko et al., 2007) and sPLA2-IIC (Molloy 
et al., 1998) while low expression of sPLA2-IIA, sPLA2-V (Molloy et al., 1998) and 
sPLA2-X (Kolko et al., 2006) in the cortex are also consistent with other reports. 
The real time RT-PCR findings are consistent with the results of a previous study, 
which showed high level of expression of sPLA2-XIIA mRNA in the whole mouse 
brain (Ho et al., 2001), and a study which showed greater iPLA2 than cPLA2 
mRNA expression in most parts of the brain (Ong et al., 2010). 
Chapter 1 





The results of Western immunoblot analyses were in general consistent 
with that of real time RT-PCR, and the PFC showed high level of protein 
expression. Two exceptions were the olfactory bulb and striatum, which showed 
differing mRNA and protein expression levels. Such phenomenon could possibly 
be accounted by RNA interference whereby microRNA (miRNA) interacts with 
sPLA2-XIIA mRNA sequences thereby preventing ribosomal protein translation 
activity (Fire et al., 1998). This theory supports the possible function of sPLA2-
XIIA in olfactory development where protein expression is more critical in the 
developmental stage than in fully developed adult rats (Muñoz-Sanjuán and 
Brivanlou, 2005). The 24 kDa band detected on western blots in the adult brain is 
consistent with the predicted 21 kDa molecular weight of full length sPLA2-XIIA 
that has undergone glycosylation post translational modification that has been 
shown to occur with other PLA2 isoforms (Gronich et al., 1994; Leslie, 1997). The 
24 kDa full length sPLA2-XIIA protein in the adult rat brain suggests that it is 
secreted into the extracellular space to perform its function. On the contrary, the 
18 kDa band in cultured SH-SY5Y cells, PC12 cells or the developing brain could 
represent a form of sPLA2-XIIA without signal peptide. The presence of a 
putative signal peptide-absent sPLA2-XIIA could indicate a form that is unable to 
undergo secretion in simpler functional systems. Blots incubated with antigen-
absorbed antibody showed absence of bands, confirming specificity of the 
antibody.  
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LOCALIZATION OF GROUP XIIA sPLA2 IN VARIOUS 










 sPLA2-XIIA is a 21 kDa enzyme that shares homology in the histidine and 
aspartate catalytic dyad  as other sPLA2 isoform (Muñoz-Sanjuán and Brivanlou, 
2005). A full length sPLA2-XIIA protein constitutes an upstream signal peptide, 
Ca2+ binding loop and downstream active site. The role of the enzyme is 
unknown although studies indicates an ability to exterminate gram-negative 
bacteria such as E. Coli and Helicobacter pylori (Koduri et al., 2002; Huhtinen et 
al., 2006). In the brain, sPLA2-XIIA is found to be involved in developmental 
defects in olfactory sensory structures that include olfactory bulb and sensory 
epithelia in the X. laevis (Muñoz-Sanjuán and Brivanlou, 2005). 
 The brain is made up of different components – neurons, glial cells 
(astrocytes and oligodendrocytes), grey matter and white matter, that contribute 
specific functions which is critical to maintain the performance of the brain. The 
majority of the brain is composed of neurons that are significant in carrying 
important information via electrical impulses during synaptic transmission. A 
typical neuron constitutes dendrites and an axon (myelinated and non-myelinated) 
that branches out into various axon terminals. Differentiation of various neuronal 
types is dependent on the neurotransmitter it carries – excitatory neurons 
generally manufacture glutamate and acetylcholine while GABAergic neurons are 
inhibitory in nature. The glial cells are non-neuronal cells that help to maintain the 
homeostatic balance, support neurons, provide nutrients to neuronal cells and 
destroy pathogens. In particular, astrocytes build the blood brain barrier and 
assist in the recycling of glutamate that has been released into the synaptic cleft 
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via the glutamine-glutamate cycle while oligodendrocytes serve its function by 
coating neuronal axons, forming myelin in the process.  
The results in chapter one concluded that sPLA2-XIIA is the highest 
expressing PLA2 isoforms in the cortex and hippocampus. Its mRNA levels were 
also the highest in all CNS regions, as compared to the well studied cPLA2-IVA 
and iPLA2-VI isoforms. The high level of expression of sPLA2-XIIA in various 
parts of the CNS suggests that it might play physiological or housekeeping 
functions in the brain. Therefore, the current study will be performed to elucidate 
the localization of sPLA2-XIIA in the CNS to further understand the possible role 












2.2.2  Materials and Methods 
2.2.2.1 Immunohistochemistry 
Six adult Wistar rats were used for this portion of the study. They were 
deeply anesthetized and perfused through the left cardiac ventricle with a 
solution of 4% paraformaldehyde and 0.1% glutaraldehyde in 0.1 M phosphate 
buffer (pH 7.4). The brains were removed and sectioned coronally at 100 µm 
using a vibrating microtome. Sections were washed for 3 hr with phosphate-
buffered saline (PBS) and incubated overnight at 4 oC with an affinity purified 
rabbit polyclonal antibody to sPLA2-XIIA (Novus Biologicals), diluted 1:50 in PBS. 
Peptide competition assay was carried out using antigen-absorbed antibody as 
described above. Sections were incubated for 1 hr in a 1:200 dilution of 
biotinylated horse anti-rabbit IgG (Vector, Burlingame, CA), reacted for 1 hr with 
avidin-biotinylated horseradish peroxidase complex, and visualized by treatment 
for 5 min in 0.05% 3, 3-diaminobenzidine tetrahydrochloride solution in Tris buffer 
containing 0.05% hydrogen peroxide. Some sections were mounted on glass 
slides and counterstained with methyl green before coverslipping. The remaining 
sections were processed for electron microscopy.  
 
2.2.2.2 Electron Microscopy 
Electron microscopy was carried out by subdissecting some of the 
immunostained sections of the PFC into smaller portions. These were fixed and 
stained with osmium for 1 hr. Thereafter, they were dehydrated in an ascending 
series of 25%, 50%, 75%, 100% ethanol and 100% acetone. The sections were 
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embedded in Araldite under various conditions – 45 mins at 45 oC, 45 mins at 55 
oC and overnight at 65 oC. Thin sections of 100 nm were obtained from the first 5 
µm of the tissue samples, mounted on copper grids coated with Formvar, and 
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2.2.3  Results 
2.2.3.1 sPLA2-XIIA Localization in Forebrain
 
Figure 2.2.3.1. Light micrographs of sPLA
Prefrontal cortex probed with sPLA
immunostaining (B) Olfactory Bulb (C
gyrus (G) Hippocampal CA1 field (H) 
general staining in the neuronal cell bod
70µm 
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 under Light Microscopy
2-XIIA immunoreactive brain slices in the forebrain. (A) 
2-XIIA antigen absorbed antibody showing absence of 
 & D) Dorsolateral prefrontal cortex (E) Striatum (F) Dentate 
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2.2.3.2 sPLA2-XIIA Localization in Hindbrain
 
Figure 2.2.3.2. Light micrographs of sPLA
brain stem and spinal cord. Light micrographs were pictured at 20X magnification. (A) Cerebellum 
probed with sPLA2-XIIA antigen absorbed antibody showing absence of immunostain
Cerebellum (C) Deep cerebellar nuclei (D) Periaqueductal gray (E) Substantia nigra (F) Dorsal 
and ventral cochlear nuclei (G) Facial motor nuclei (H) Spinal trigeminal nuclei. Dense staining 
were observed in B-D and F
dopaminergic neurons and spinal trigeminal nuclei. Scale: 
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 under Light Microscopy
2-XIIA immunoreactive brain slices in the cerebellum, 
-G brain sections while light staining was found in substantia nigra 












Sections incubated with antigen-absorbed antibody showed absence of 
immunostaining (Figure 2.2.3.1A and 2.2.3.2A). Moderately dense staining was 
observed in neuronal cell bodies in the olfactory bulb (Figure 2.2.3.1B), 
dorsolateral PFC (Figure 2.2.3.1C & 2.2.3.1D), striatum (Figure 2.2.3.1E) and 
hippocampal formation including the dentate gyrus (Figure 2.2.3.1F), CA1 
(Figure 2.2.3.1G) and CA3 fields (Figure 2.2.3.1H). In comparison, less dense 
immunostaining was observed in the hindbrain, with the exception of cerebellar 
Purkinje neurons (Figure 2.2.3.2B), deep cerebellar nuclei (Figure 2.2.3.2C), 
periaqueductal gray (Figure 2.2.3.2D), dorsal and ventral cochlear nuclei (Figure 
2.2.3.2F) and the facial motor nucleus (Figure 2.2.3.2G). Neurons of the 
substantia nigra (Figure 2.2.3.2E) and spinal trigeminal nucleus (Figure 2.2.3.2H) 
were lightly stained.  
  
Localization of Group XIIA sPLA
 
2.2.3.3        sPLA2-XIIA Localization in 
 
Figure 2.2.3.3. Electron micrograph of sPLA
cortex. Staining is observed in (A & B) axon pre
pre-terminals contained syna
A & C = 0.1 µm, B = 100 nm 
 
 
Electron microscopy of immunostained sections of the PFC showed 
staining mostly in axon pre
staining in dendrites (Figure
synaptic vesicles, but did not form mature synaptic contacts with dendrites. The 
results suggest that sPLA
axonal growth cones in t
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the cortex under Electron Microscopy
2-XIIA immunoreactive sections from the prefrontal 
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Immunohistochemical analyses showed moderately dense sPLA2-XIIA 
immunoreactivity in the forebrain including the PFC and hippocampal CA3 field, 
while lighter staining was detected in the olfactory bulb, striatum, dentate gyrus 
and the hippocampal CA1 field. Immunolabelling was also observed in cerebellar 
Purkinje neurons, deep cerebellar nuclei, periaqueductal gray, dorsal and ventral 
cochlear nuclei and the facial motor nucleus. The dense immunoreactivity in the 
olfactory bulb is consistent with a role of sPLA2-XIIA in olfactory neurogenesis 
(Muñoz-Sanjuán and Brivanlou, 2005). The presence of sPLA2-XIIA in the dorsal 
lateral pre-frontal cortex and hippocampus in the forebrain signify that the protein 
might be involved in LTP facilitated learning and memory (Laroche et al., 1990). 
Immunoreactivity to sPLA2-XIIA in the striatum, cerebellar Purkinje cells, deep 
cerebellar nuclei and the facial motor nucleus suggest that sPLA2-XIIA could be 
involved in motor functions. The presence of sPLA2-XIIA in the periaqueductal 
gray but absence in spinal trigeminal nuclei implies that sPLA2-XIIA does not 
participate in analgesia. This corresponds to findings of insignificant sPLA2-XIIA 
gene expression changes after carrageenan induced orofacial pain (Ma et al., 
2012). The presence of sPLA2-XIIA in the dorsal and ventral cochlear nuclei 
could indicate a role in auditory functions. Unlike sPLA2-IIA and sPLA2-IIE, 
expression of sPLA2-XIIA is not affected after spinal cord injury (Titsworth et al., 
2009). Together, the high expression level of sPLA2-XIIA in various parts of the 
rat brain strongly suggests physiological roles in the normal brain.  
Chapter 2 





Electron microscopic study shows sPLA2-XIIA immunostaining in the axon 
pre-terminals. Reaction product was localized away from the active zones of 
synapses, indicating that sPLA2-XIIA is not directly involved in synaptic 
transmission. The axons contained synaptic vesicles but did not form mature 
synaptic contacts with dendrites. The results suggest that sPLA2-XIIA may be 
associated with immature axon terminals or growth cones. sPLA2 has been 
shown to be involved in neurite outgrowth of immature neurons (Nakashima et 
al., 2003), and a role of sPLA2-XIIA has been proposed in olfactory neurogenesis 
(Muñoz-Sanjuán and Brivanlou, 2005). Neuritogenic effect can be induced by 
sPLA2-IIA via an intracellular mechanism (Ferrini et al., 2010), or sPLA2-III and 
sPLA2-X via lipolytic production of lysoPC (Masuda et al., 2005b; Masuda et al., 
2008). The location of sPLA2-XIIA could facilitate the neuritogenic effect of its 
metabolites, AA (Williams et al., 1994; Smalheiser et al., 1996) and lysoPC 
(Ikeno et al., 2005). It is possible that these neurogenic or neuritogenic functions 
may not be just limited to olfactory structures, but includes other brain regions, 
since sPLA2-XIIA is present across different brain regions.  
The localization of sPLA2-XIIA in the post-synaptic elements was also 
similar to the observation in sPLA2-IIA (Ma et al., 2010a). sPLA2-XIIA has a 
strong secretory signal which might contribute to its secretion in the neurons. It 
can be postulated that secretion of sPLA2-XIIA in the post-synaptic density might 
generate lysoPI from PI and be significant in neural transmission (Ma et al., 
2010b). Besides that, sPLA2-XIIA possible downstream arachidonic acid 
metabolite was reported to act as retrograde messengers from post-synaptic 
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dendrites during the induction of long term potentiation (LTP) (Williams et al., 
1989). These messengers are able to cross the synapse by diffusion and exert 
effects in the pre-synaptic axon terminals resulting in sustained generation of 
action potential during LTP (Bliss et al., 1986; Bekkers and Stevens, 1990; 
Malinow and Tsien, 1990). Localization of sPLA2-XIIA in glutamatergic neurons 
also supports LTP which requires activation of the N-methyl-D-aspartate (NMDA) 
receptors. The consequent increase in Ca2+ influx at the post-synaptic neurons 
(O'Dell et al., 1991) will cause further sPLA2-XIIA secretion back into the pre-

















CHANGES IN PREFRONTAL CORTICAL LIPID PROFILE 











Changes in prefrontal cortical lipid profile of Group XIIA sPLA
 
2.3.1 Introduction 
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 Five different common 
glycerophospholipids 
Lysophospholipids do not form the membrane lipid bilayer due to its structure 
hindrance (Fuller and Rand, 2001
micelles if present at low concentrations. However, at high c
lysophospholipids will perturb membrane integrity by acting as a detergent
molecule, which may in turn cause toxicity to cells 
Figure 2.3.1.2. Metabolism of sphingomyelin and sphingolipids. Their downstream 






types of lysophospholipids are generated from 
– lysoPA, lysoPC, lysoPE, lysoPI and lysoPS. 







). High amount 
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of lysophospholipids are found at pathological conditions, with its action affecting 
membranal ion exchanges and proteins, leading to a disruption in signal 
transduction and cell lysis (Farooqui and Horrocks, 2006). 
 Sphingolipids are a major class of lipids that contain sphingoid bases 
backbone which is generally found in membranes of eukaryotes. The huge lipid 
class can be classified based on its head groups, which includes ceramides, 
sphingomyelin, glucosylceramide and gangliosides. The sphingomyelin acts as 
membranous sheath by surrounding cell axons and facilitates signal transduction 
(Kolesnick, 1994). On the other hand, the physiological functions of ceramides 
include its involvement in apoptosis, cell differentiation, cell migration and 
adhesion (Hannun and Obeid, 2008). Pathological conditions such as Gaucher 
disease is found during the occurrence of glucosylceramide overabundance 
while the Tay-Sachs disease arises due to a autosomal recessive deficiency in 
hexosaminidase A that causes the accumulation of gangliosides in neuronal cells 
(Navon et al., 1973). 
 In view of the significance of these lipid species in the brain, the 
elucidation of sPLA2-XIIA’s target substrate will allow for the understanding of its 
physiological roles in the brain. Therefore, knockdown studies will be carried out 
using antisense sPLA2-XIIA Locked Nucleic Acid (LNA) that targets sPLA2-XIIA 
mRNA, thereby preventing the translation of the sPLA2-XIIA protein. Lipidomic 
analyses by tandem mass spectrometry will be conducted on sPLA2-XIIA 
antisense and sense injected rats, to elucidate the possible differences in brain 
lipids.  
Chapter 3 





2.3.2  Materials and Methods 
2.3.2.1 Intracortical Injection of Antisense Locked Nucleic Acid 
Six adult male Wistar rats were used for this portion of the study. A 16-
base antisense phosphorothioate modified LNA/DNA gap-mer corresponding to 
sPLA2-XIIA sequence (5’-CTATCCAGGTACGGC-3’) and a 16-base scrambled 
sense control (5’-GACGGTAACTAGGCGA-3’) were designed and synthesized 
by Exiqon (Rudersdal, Denmark). LNA oligonucleotides were chosen due to their 
stability and high affinity binding to mRNA sequences in vivo. Rats were 
anaesthetized with ketamine and xylazine cocktail and placed on a stereotaxic 
apparatus (Stoelting, USA). Two small craniotomies were made over the PFC on 
each side, and 2 µl of antisense oligonucleotide (50 µM) or sense oligonucleotide 
(50 µM) were injected using a Hamilton syringe at each site over 5 min 
(coordinates: 3.5 mm or 4.0 mm rostral to bregma; 1.5 mm lateral to midline and 
2.0 mm from surface of cortex), and the scalp sutured. 
 
2.3.2.2  Western blot to show knockdown of sPLA2-XIIA 
Six male Wistar rats for each injection group i.e. antisense LNA or sense 
LNA were used in this portion of the study, to demonstrate the effectiveness of 
sPLA2-XIIA antisense knockdown. Rats were sacrificed four days after LNA 
injection. The brains were removed and a region of the PFC between the frontal 
pole and the caudate-putamen dissected out and homogenized. Western blot 
analyses were carried out as described above. Band intensities were quantified 
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by densitometric analyses. The means were compared using two tail unpaired 
Student’s t-test. p < 0.05 was considered significant. 
 
2.3.2.3 Lipid Extraction 
Six male Wistar rats for each injection group i.e. antisense LNA or sense 
LNA were used in this portion of the study. The left and right PFC were harvested 
four days after LNA injection. Lipids were extracted using a modified protocol of 
Bligh and Dyer (Bligh and Dyer, 1959). Tissues were homogenized in 750 µl of 
chloroform:methanol, 1:2 (v/v) using Tissue Tearor™ (Biospec, USA). Samples 
were then transferred to thermomixer (Eppendorf, USA) for mixing at 1200 g, 4 
oC for 30 mins and 250 µl chloroform and 450 µl 0.88% potassium chloride (KCl) 
added. The mixture was then vortexed and centrifugated at 9000 g, 4 oC for 2 
min. Lipids were isolated from the organic phase, vacuum dried (Thermo Savant 
SpeedVac, USA) and resuspended in chloroform:methanol (1:1 v/v) for analysis. 
 
3.2.4 Lipid Analyses using Liquid Chromatography/Mass Spectrometry 
The lipids were analyzed using an Agilent 1200 HPLC system coupled 
with an Applied Biosystem Triple Quadrupole/Ion Trap mass spectrometers 
3200Qtrap as described previously (Shui et al., 2011a; Shui et al., 2011b). 
Separation of individual polar lipids was carried out using a Phenomenex Luna 
3u silica column (i.d. 150 x 2.0 mm) with the following conditions: mobile phase A 
(chloroform:methanol:ammonium hydroxide, 89.5:10:0.5), B 
(chloroform:methanol:ammonium hydroxide:water, 55:39:0.5:5.5). Individual 
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polar lipid levels were quantified using spiked internal standards that included 
PC-14:0/14:0, LPC-C20, PE
PG-14:0/14:0, C8-GluCer, C17
USA). Dioctanoyl phosphatidylinositol (PI, 16:0
lysophosphatidylinositol quantitation and obtained from Echelon Biosciences, Inc. 
(Salt Lake City, UT, USA). Free cholesterol and cholesterol esters were 
analyzed, with d6-chol
internal standards (Shui et al., 2011a
normalized to the sum of all lipid species measured
differences between the mean values were analyzed using unpaired Student’s t













-14:0/14:0, LPE-C17, PS-14:0/14:0, PA
-Cer, C12-SM (Avanti Polar Lipids, 
-PI) was used for 
esterol and d6-C18 cholesterol ester (CDN isotopes) as 
). The level of each individual lipid was 
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2.3.3  Results 








Figure 2.3.3.1. Western blots analyses of rats injected intracortically with sPLA
and sense LNA. (A) Antibody to sPLA
actin were also assayed to verify equal loading of samples. (B) Densitometric 
XIIA band intensity that were normalized to 
significantly reduced after antisense LNA injection. Asterisks indicate significant differences 

































2-XIIA detected a single band at 24kDa. Protein levels of 




















In view of the high expression level of sPLA2-XIIA in the PFC, sPLA2-XIIA 
knockdown studies were carried out to elucidate possible cellular and cognitive 
functions of sPLA2-XIIA in this brain region. Western blot analyses were 
performed on LNA antisense and sense injected rats to verify sPLA2-XIIA 
knockdown. Antisense LNA injected rats showed significant downregulation of 
the 24kDa sPLA2-XIIA protein (Figure 2.3.3.1A & 2.3.3.1B).   
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2.3.3.2 Lipidomic Analyses 
Table 2.3.3.2: Lipid species that displayed significant changes between antisense and sense LNA 
injected rats. 
  Sense Antisense  











































































































































































Glu Cer d18:1/22:0 










































































































Significant differences were found in various phospholipid species – Phosphatidic 
Acid (PA) (Figure 2.3.3.2.1), PC (Figure 2.3.3.2.2A), PE (Figure 2.3.3.2.3A & 
2.3.3.2.3B), PI (Figure 2.3.3.2.4A), Phosphatidylserine (PS) (Figure 2.3.3.2.5A). 
Significant increase in relative abundance was found in PA34:2, PE34p:2, 
PE38p:5, PE38p:4, PE38p:1, PE38:5, PE40p:7, PE40p:5, PE40:5, PE40:3, 
PE42:4, PI 38:6, PI 38:5, PI 38:4 and PS38:2. In contrast, lysophospholipids 
including LysoPC 16:1, LysoPC 16:0, LysoPC 18:0e, LysoPC 18:0 (Figure 
2.3.3.2.2C), LysoPE 16:0, LysoPE18:1p (Figure 2.3.3.2.3C), LysoPI 20:4 (Figure 
2.3.3.2.4B) and LysoPS 18:0 (Figure 2.3.3.2.5B) were found to be significantly 
lowered in antisense LNA injected rats. Significant decrease in relative 
abundance was observed in PC32:2e, PC32:1e (Figure 2.3.3.2.2A), PE42p:7 
(Figure 2.3.3.2.3B), PI 32:2 and PI 34:2 (Figure 2.3.3.2.4A) lipid species in 
sPLA2-XIIA antisense LNA injected rats. 
Decrease in relative abundance of Sphingomyelin (SM) including 
SM18:1/16:1, SM18:0/16:0, SM18:1/18:0, SM18:1/22:0 and SM18:1/24:0 (Figure 
2.3.3.2.6B) was found, whilst Ceramide (Cer) d18:1/20:0, Cer d18:1/22:0, Cer 
d18:1/24:1 (Figure 2.3.3.2.7A), Glucosylceramide (GluCer) d18:1/22:0, GluCer 
d18:0/22:0 (Figure 2.3.3.2.7B), Ganglioside3 (GM3) 18:1/16:1, GM3 18:1/18:0, 
GM3 18:0/18:0, GM3 18:1/20:0, GM3 18:1/20:0, GM3 18:1/22:1, GM3 18:1/24:1 
(Figure 2.3.3.2.8) and Sphingolipid (SL) d18:1/20:0 and SL d18:1/24:1 (Figure 









2.3.3.2.1     Phosphatidic Acid 
 
Figure 2.3.3.2.1. Relative abundances of Phosphatidic Acid in the prefrontal cortex of antisense 
LNA and sense injected rats. The mean and standard errors are presented. Asterisks indicate 
significant differences in relative abundances between antisense LNA and sense injected rats 






































































































Figure 2.3.3.2.2. Relative abundances of (A & B) Phosphatidylcholine and (C) 
Lysophosphatidylcholine in the prefrontal cortex of antisense LNA and sense injected rats. The 
mean and standard errors are presented. Asterisks indicate significant differences in relative 
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Figure 2.3.3.2.3. Relative abundances of (A & B) Phosphatidylethanolamine and (C) 
Lysophosphatidylethanolamine in the prefrontal cortex of antisense LNA and sense injected rats. 
The mean and standard errors are presented. Asterisks indicate significant differences in relative 
abundances between antisense LNA and sense injected rats with p-value of <0.05 (*) and <0.01 

































2.3.3.2.4     Phosphatidylinositol and Lysophosphatidylinositol  
 
 
Figure 2.3.3.2.4. Relative abundances of (A) Phosphatidylinositol and (B) 
Lysophosphatidylinositol in the prefrontal cortex of antisense LNA and sense injected rats. The 
mean and standard errors are presented. Asterisks indicate significant differences in relative 
abundances between antisense LNA and sense injected rats with p-value of <0.05 (*) and <0.01 
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2.3.3.2.5     Phosphatidylserine and Lysophosphatidylserine 
 
 
Figure 2.3.3.2.5. Relative abundances of (A) Phosphatidylserine and (B) Lysophosphatidylserine 
in the prefrontal cortex of antisense LNA and sense injected rats. The mean and standard errors 
are presented. Asterisks indicate significant differences in relative abundances between 




























































2.3.3.2.6     Sphingolipid and Sphingomyelin 
 
 
Figure 2.3.3.2.6. Relative abundances of (A) Sphingolipid and (B) Sphingomyelin in the prefrontal 
cortex of antisense LNA and sense injected rats. The mean and standard errors are presented. 
Asterisks indicate significant differences in relative abundances between antisense LNA and 


























































2.3.3.2.7     Ceramide and Glucosyl-Ceramide 
 
 
Figure 2.3.3.2.7. Relative abundances of (A) Ceramide and (B) Glucosyl Ceramide in the 
prefrontal cortex of antisense LNA and sense injected rats. The mean and standard errors are 
presented. Asterisks indicate significant differences in relative abundances between antisense 





























































2.3.3.2.8     Gangliosides 
 
Figure 2.3.3.2.8. Relative abundances of Gangliosides in the prefrontal cortex of antisense LNA 
and sense injected rats. The mean and standard errors are presented. Asterisks indicate 
significant differences in relative abundances between antisense LNA and sense injected rats 






































LNA antisense knockdown was further carried out, to elucidate a possible 
role of sPLA2-XIIA in lipid metabolism or cognitive functions, involving the PFC. 
Lipidomic analyses showed that sPLA2-XIIA have an effect on phospholipid 
profiles in the brain. The changes in phospholipids for antisense LNA injected 
rats including PE, PI and PS showed that sPLA2-XIIA possess inherent 
enzymatic activity. In particular, increase in PE together with decrease in LysoPE 
species suggests that sPLA2-XIIA is involved in membrane PE metabolism. 
Based on the molecular weight of the PE and LysoPE or PI and LysoPI species, 
it is possible that AA is selectively released by action of sPLA2-XIIA e.g. PE38p:5 
is cleaved to form LysoPE18:1p and AA, i.e. 38:5 minus 18:1 = 20:4 or 
arachidonic acid. Likewise, PI 38:4 is cleaved to produce LysoPI 18:0 and AA. 
The liberation and metabolism of AA occurs with the generation of lipid second 
messengers (Farooqui and Horrocks, 2006). This effect of sPLA2-XIIA is different 
from iPLA2, which releases DHA (Ong et al., 2010). Since PE is the main lipid 
species of microbial membranes (Murzyn et al., 2005), the results are consistent 
with a reported high efficacy of sPLA2-XIIA against E. coli (Koduri et al., 2002) 
and Helicobacter pylori (Huhtinen et al., 2006), which has high PE content in its 
membranal structures. On the contrary, studies have shown that sPLA2-IIA, 
sPLA2-V and sPLA2-X have higher efficacy against PC rich vesicles. In 
comparison, sPLA2-XIIA was found to have low binding affinity to the sPLA2 M-
type receptor (Rouault et al., 2007).  
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The decrease in relative abundance in sphingomyelin (SM) and increase 
in ceramide (Cer) also suggest that an indirect effect of sPLA2-XIIA on the SM 
metabolizing enzyme, sphingomyelinase (Reynolds et al., 2004). Gangliosides 
(GM) have also been shown to be involved in neuronal plasticity and repair 
(Mocchetti, 2005) and are also increased in sPLA2-XIIA antisense LNA injected 
rats. No changes in cholesterol metabolism were detected. These results show 
an important role of sPLA2-XIIA in glycerophospholipid and sphingolipid 
metabolism in the brain. 
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 The PFC lies in the brain’s anterior frontal lobes, in front of the motor and 
premotor areas. This region of the brain has been shown to be involved in high-
order thinking, cognition (Koechlin et al., 1999), decision making, working 
memory (Funahashi and Kubota, 1994), attention (Dias et al., 1996) and 
regulating social behaviour (Yang and Raine, 2009). It can be further 
distinguished based on its anatomical positions in the brain – frontal pole, 
dorsolateral frontal cortex, mid-ventrolateral frontal cortex and orbitofrontal cortex.  
The frontal pole or rostral frontal cortex (Brodmann area 9 and 10) is the 
most anterior portion of the frontal lobe that has so far not been associated with 
any functional description. On the contrary, the dorsolateral frontal cortex 
(Brodmann area 9 and 46) is implicated with various brain functions including 
cognition (Goldman-Rakic, 1994; Courtney et al., 1998), working memory (Owen, 
1997), planning (Fletcher et al., 1998) and recalling long-term memory (Rugg et 
al., 1998). On the other hand, the mid-ventrolateral frontal cortex (Brodmann 
area 47) is activated during decision making (Petrides, 1994), holding transient 
information (Courtney et al., 1997), switching between learned tasks (Dove et al., 
2000), reversal learning (Cools et al., 2002), retrieving cues (Dobbins et al., 2002) 
and encoding information to form episodic memory (Wagner et al., 1998; Henson 
et al., 1999). Finally, the orbitofronal cortex is responsible for the induction of 
motivation and emotions based on taste, smell and touch (Rolls, 2000), 
associating arbitrary stimulus with rewards or punishments (Tremblay and 
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Schultz, 1999) and integrating these learnt information in decision making and 
responses (Dias et al., 1996; Elliott et al., 2000; Roberts and Wallis, 2000). 
 The Wisconsin Card Sorting Test (WCST) has been a widely used test for 
neuropsychological conditions of “set-shifting” i.e. ability to shift attention under 
changing situational cues (Monchi et al., 2001). The WCST is formally designed 
for the use in primate species to test for such attention shifting between 
perceptual features of the stimuli (Owen et al., 1991). When faced with a 
perceptual stimulus, it would be easier to discriminate a novel stimulus if the rule 
is based on similar perceptual discrimination [Intra-Dimensional shift]. On the 
contrary, the acquisition of a stimulus that requires the shifting of attention to a 
differing perceptual discrimination [Extra-Dimensional shift] would require a 
longer learning period (Birrell and Brown, 2000). Thus, a new task that is 
designed specifically for rodents would be required to test for attention set-
shifting deficits in rats. The Attentional Set-Shifting Task (ASST) can be used to 
test for medial frontal cortex impairments in rodents for attention shifting between 
testing paradigms which may implicate reversal learning difficulties to 
discriminate stimuli (Bussey et al., 1997) and delayed response task (Delatour 
and Gisquet-Verrier, 1999). This test incorporates both the intradimensional 
(ID)/extradimensional (ED) tasks that allows for both learnt response which forms 
attention sets and the ability to shift within the rules of ID and ED dimensions 
(Owen et al., 1991). Deficiencies in these set shifting task has been reported in 
functional neuroimaging studies in Schizophrenic patients and patients with 
frontal lobe lesions. (Weinberger et al., 1992; Volz et al., 1997). 
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 The Passive Avoidance (PA) test has been used as a tool to assess 
memory functions based on the association of a stimulus (i.e. foot shock) and 
their environmental conditions. The test engages the concept of rat’s preference 
for dimly lit conditions over a brightly lit environment. During the study, the rats 
are placed in a brightly-lit compartment and a foot shock will immediately be 
administered upon its entry into the dimly lit compartment. Analysis of memory 
function is based on the latency timing that the rat took to enter the shock-paired 
compartment as the rats would have learnt to avoid the dimly lit compartment 
that is coupled with foot shock.  
 The previous three chapters have shown how sPLA2-XIIA might play 
significant functions in the PFC. The ASST will be performed to investigate 
sPLA2-XIIA potential role in attentional sets, reversal learning and switching 
between learnt tasks that is controlled mainly by the mid-ventrolateral frontal 
cortex and the induction of motivations and rewards system that is governed by 
the orbitofrontal cortex. Furthermore, working memory testing will also be carried 









2.4.2  Materials and Methods 
2.4.2.1 Attentional Set-Shifting Task 
Six male Wistar rats for each injection group i.e. antisense LNA or sense 
LNA were used in this portion of the study. Rats were tested in the ASST four 
days after LNA injection. The procedures of the test are similar to that reported 
previously (Birrell and Brown, 2000; Young et al., 2010) and were conducted in a 
blinded manner. Rats were trained to dig in ceramic bowls to retrieve food 
rewards based on olfactory cues (Birrell and Brown, 2000; Young et al., 2010). 
Ceramic pots (5 cm x 4 cm) were used as digging bowls and placed on platforms 
(25 cm x 10 cm x 1 cm) in the testing apparatus. The test apparatus was an 
adapted home cage (40 cm x 30 cm x 20 cm) with two digging bowls placed at 
two different corners of the cage. Access to these bowls was limited by removal 
dividers. Odors that were used as guiding cues were purchased from 
Masterfoods® (Australia) and included powered spices like ground ginger, 
nutmeg, coriander, garlic, thyme and cinnamon. Platforms with different surface 
textures comprising of sandpaper, wood, metal wire, perspex, paper and fabric 
were used as the second dimension in this study. The food reward was a single 5 
mm x 5 mm food pellet for each correct trial. The rats were acclimatized to the 
testing apparatus and digging bowls three days after intracortical injection 
surgery. The rats were trained to dig in unscented bedding for food rewards. 
After the rats were digging reliably for food rewards, they were exposed to the 
various digging bowls and platforms that they would encounter during the actual 
task. The criterion for a successful dig was defined as when the nose or paws 
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Table 2.4.2.1: Descriptions of stages within the Attentional Set-Shifting Task 
Discriminations 
Dimensions Exemplar Combinations 
Relevant Irrelevant Positive Negative 
Simple (SD)  Odor  Platform  O1  O2  
Compound (CD)  Odor  Platform  
O1/P1  O2/P2  
O1/P2  O2/P1  
Compound 
Reversal (CDR)  Odor  Platform  
O2/P1  O1/P2  
O2/P2  O1/P1  
Intradimensional 
Shift (IDS)  Odor  Platform  
O3/P1  O4/P2  
O3/P2  O4/P1  
Intradimensional 
Reversal (IDR)  Odor  Platform  
O4/P1  O3/P2  
O4/P2  O3/P1  
Extradimensional 
Shift (EDS)  Platform  Odor  
O5/P1  O6/P2  
O6/P1  O5/P2  
Extradimensional 
Reversal (EDR)  Platform  Odor  
O5/P2  O6/P1  
O6/P2  O5/P1  
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broke the surface of the digging medium. This criterion was used throughout 
testing.  
Trials were initiated by raising the divider allowing access to the two 
digging bowls, of which only one is baited. For the first four trials, the rats were 
permitted to dig in both digging bowls to allow for cue contingency. Errors would 
then be recorded in subsequent trials when rats dug in unbaited bowls, and the 
trial will be restarted. Trials would continue until 6 consecutive successful digs 
were attained. Throughout the whole testing paradigm, the rats would have to 
perform a series of discriminations whereby baited bowls are selected based on 
a stimulus in a particular dimension, odor or platform surface texture. Examples 
of discriminations that the rats were required to make can be found in Table 
2.4.2.1. For instance, in simple discrimination (SD), the only relevant dimension 
present is odor. Compound discriminations (CD) would introduce an extra 
irrelevant dimension, platform, with the relevant odor in SD used to identify the 
correct bowl. The first compound reversal (CDR) would require the rats to 
respond to the previously irrelevant odor. After which, two novel odors will be 
presented in the intradimensional shift (IDS) and only one bowl is baited. The 
second intradimensional reversal (IDR) would require the rats to respond to the 
previously irrelevant odor. Lastly, the rats will be put through an extradimensional 
shift (EDS), wherein the previously irrelevant dimension (platform), would be 
relevant. The third extradimensional reversal task (EDR) would require the rats to 
respond to the previous irrelevant platform stimulus. At each stage, the rats 
would have to attain six consecutive successful trials before being allowed to 
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move onto the next stage. Trials to criterion and number of errors were recorded 
for each stage. Differences in the number of trials to criterion and errors were 
analyzed using non-parametric Mann-Whitney test. p < 0.05 was considered 
significant. 
 
2.4.2.2 Passive Avoidance 
Twelve male Wistar rats for each injection group i.e. antisense LNA or 
sense LNA were used in this portion of the study. Rats were tested in the passive 
avoidance task four days after LNA injection. Passive avoidance was measured 
using a PACS-30 system (Columbus Instruments, Ohio, USA), which consists of 
a two-compartment shuttle chamber with a constant current shock generator. On 
the acquisition trial, rats were placed into the start chamber, which remained 
darkened. After 20 s, the chamber light was illuminated and the door was opened 
for the rats to move into the dark chamber freely. Immediately after they entered 
the dark chamber, the door was closed and an inescapable electric shock (0.3 
mA, 3 s, once) delivered through the floor grid. The rats were then returned to 
their home cages. One and twenty-four hours later, each rat was again placed in 
the start chamber (retention trial). The interval between the placement in the 
lighted chamber and the entry into the dark chamber was measured as the step-
through latency in both acquisition and retention trials (maximum 300 s). A 
shorter latency period indicates its inability to retain previously formed memory of 
the electric shock. Possible differences between the mean values were analyzed 
using non-parametric Mann-Whitney test. p < 0.05 was considered significant. 
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2.4.3  Results 
2.4.3.1 Attentional Set-Shifting Task 
  
 
Figure 2.4.3.1. (A) Number of trials required to achieve 6 consecutive success. (B) Number of 
errors made during Attentional Set Shifting Task procedure. SD: Simple Discrimination, CD: 
Compound Discrimination, CDR: Compound Discrimination Reversal, IDS: Intradimensional Shift, 
IDR: Intradimensional Reversal, EDS: Extradimensional Shift, EDR: Extradimensional Reversal. 
Data represent the mean and standard error from 6 Wistar rats. Significant differences were 
observed for CDR, IDS and IDR tasks for both the number of trials required to reach criterion and 




























































Rats injected with antisense LNA required more trials to complete six 
consecutive successful attempts as compared to sense injected rats (Figure 
2.4.3.1A). The number of errors committed during the trials was also greater in 
antisense treated rats (Figure 2.4.3.1B). Significant differences were observed 
for CDR, IDS and IDR tasks for both the number of trials required to reach 
criterion and number of errors committed. Incomplete data acquisition was 
recorded for antisense-LNA injected rats during EDS and EDR due to rats’ 
disinterest in food rewards. Although statistical tests were omitted for these 2 
tasks, the number of trials required for antisense LNA injected rats to complete 
the stages was higher than the sense injected rats. Higher number of trials to 
criterion and errors committed further confirmed that the antisense treated rats 
have impairments in attention.  
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2.4.3.2 Passive Avoidance 
 
 
Figure 2.4.3.2. Passive avoidance performance of sPLA2-XIIA antisense and sense LNA injected 
rats (A) 1 hour after training (B) 24 hours after training. No significant differences were found in 
both sets of treated rats for acquisition task 1 hr and 24 hrs after training. For short term memory 
(1 hr after training), antisense rats displayed a significantly shorter latency period. Furthermore, 
long term memory (24 hrs after training) was also significantly reduced to a greater extent. 






































































No significant differences were found between the treated rats in the 
acquisition task 1 hr and 24 hrs after training. At 1 hr after training, antisense 
LNA treated rats showed shorter latency period with mean latency of 189 s, 
compared to 256 s in sense treated rats (Figure 2.4.3.2A). The time latency for 
long term memory (24 hrs after training) was reduced by an even greater extent, 
with mean latency of 72 s recorded in antisense LNA injected rats compared to 
218 s in sense LNA injected rats (Figure 2.4.3.2B). The shorter latencies at 1 hr 
and 24 hrs after training in sPLA2-XIIA knockdown rats indicate poorer short- and 
long-term memories.  
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The passive avoidance (PA) test is widely used as a test of recognition 
memory. The behavioral effects of sPLA2-XIIA inhibition were also studied. 
Shorter latency period in the PA test as detected in antisense LNA injected rats 
indicates their inability to retain previously formed memories of the electric shock. 
The deficits suggest impairment of short- and long term working memories. The 
results are consistent with previous studies which showed that neurons in the 
dorsolateral PFC are active during working memory tasks (Goldman-Rakic, 
1990). The deficits shown in antisense rats in PA suggest impairment of both 
declarative and non-declarative working memories which are evident in most 
Attention Deficit/Hyperactivity Disorders (ADHD) patients (McInnes et al., 2003; 
Valera et al., 2005; Piek et al., 2007). In particular, dopamine D1 receptor 
involved in the formation of memories and antagonizing these receptors was 
shown to impair memory functions (Arnsten, 1997). This correlates to the 
hypodopaminergic states in ADHD patients (Solanto, 2002), whereby dopamine 
is critically involved in neuronal projections into the prefrontal cortex which 
shapes cognitive functions in the brain (Cabral, 2006). 
 Another test of PFC function that is related to cognition is ASST. The task 
is mainly aimed at studying attentional span for animals, which may be linked to 
several diseases such as ADHD, autism, schizophrenia, depression and 
Parkinson’s disease (Gattaz and Brunner, 1996; Talbot et al., 2000; Lee et al., 
2012). We found that antisense LNA injected rats display a higher number of 
trials to criterion and number of errors, indicating that these rats have poor 
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abilities to switch between arbitrary internal rules guiding behavior known as 
‘cognitive-attentional sets’. Significant differences in the total number of trials 
taken for CDR, IDS and IDR stages suggest that antisense LNA treated rats 
have impaired abilities in switching between previously learnt tasks. Furthermore, 
the number of errors recorded for sPLA2-XIIA antisense LNA injected rats was 
significantly higher in the CDR, IDS and IDR stages. sPLA2-XIIA antisense rats 
were also observed to be less motivated by food rewards and exhibited impulsive 
behavior, similar in ADHD patients (Puumala and Sirviö, 1998). The distinct 
deficiency in decision making and its accuracy has also been shown to affect 
ADHD via the changes of activity in dopamine and serotonin receptors (Puumala 
and Sirviö, 1998). The mechanism of action might involve neuronal 
neurotransmission in NMDA/serotonin/dopaminergic receptors (Glickstein et al., 
2005; Hatcher et al., 2005; Lapiz and Morilak, 2006) that relies on sPLA2-XIIA 
localization in the dendrites. The link between sPLA2-XIIA, ADHD and 
dopamine/serotonin functions would thus present an interesting study prospect. 
Reversal deficits have been observed in Schizophrenia patients with OFC 
pathology. Such observation is speculated to involve slowing learning abilities 
due to sPLA2-XIIA antisense knockout. The mechanism of action might involve 
neuronal neurotransmission involving sPLA2-XIIA localization in the dendrites in 
which accumulation of downstream sPLA2-XIIA metabolites might lead to 
neurotoxicity, leading to pre-frontal cortical damages. In particular, previous 
studies have shown that reduced amount of neuropil accounts for the 
pathogenesis of Schizophrenia (Braak and Braak, 1988). High genetic 
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expression of sPLA2-XIIA in the neuropils might suggest implications of sPLA2-
XIIA in Schizophrenia. Moreover, potential involvement of sPLA2-XIIA in LTP 
which is significant in the formation of working memory (Williams et al., 1989) 
further relates sPLA2-XIIA to Schizophrenia in working-memory related 
dorsolateral prefrontal cortex dysfunction (Malenka and Nicoll, 1999; Perlstein et 
al., 2001; Farooqui and Horrocks, 2004). The direct link between PLA2 and 
Schizophrenia remains to be elucidated and the connection of sPLA2-XIIA, LTP 






























In chapter one, it was found that sPLA2-XIIA was the highest expressing 
PLA2 isoform in the PFC and hippocampus. Highest amount of sPLA2-XIIA 
mRNA was observed in the PFC and olfactory bulb throughout the whole CNS. 
Under western immunoblot analyses, the results showed that highest sPLA2-XIIA 
protein expression level was found in the PFC, similar to its genomic expression 
as displayed in real-time RT-PCR. Two forms of sPLA2-XIIA were found in in vivo 
and in vitro systems – full length sPLA2-XIIA protein and signal peptide ablated 
sPLA2-XIIA protein. The signal peptide ablated sPLA2-XIIA form in postnatal rat 
pups, SH-SY5Y and PC12 cells suggests the absence of extracellular secretion 
of sPLA2-XIIA in simpler functional systems. The presence of full length sPLA2-
XIIA in adult rats however, shows that secretion of sPLA2-XIIA protein into 
extracellular spaces is significant for it to perform its function. 
In chapter two, localization of sPLA2-XIIA in the adult rat brain was 
performed using immunohistochemistry and electron microscopy. 
Immunolabelling was generally found in the forebrain, with dense 
immunostaining found in the PFC and hippocampal CA3 region. Under electron 
microscopy, the reaction product was found localized away from the active zones 
of the synapses. The axons contained synaptic vesicles but did not form mature 
synaptic contacts with dendrites. The results suggest that sPLA2-XIIA may be 
associated with immature axon terminals or growth cones. Immunolabelling 
found in occasional dendrites were suggested to be involved in LTP. 
In chapter three, knockdown studies using  sPLA2-XIIA antisense LNA in 







lysophospholipids, sphingomyelin, sphingolipid, gangliosides, ceramides and 
glucosylceramides. In particular, the increase in PE together with decrease in 
LysoPE species suggests that sPLA2-XIIA is involved in membrane PE 
metabolism which imply that sPLA2-XIIA is an enzymatically active PLA2. 
In chapter four, the behavioural studies using sPLA2-XIIA antisense LNA 
knockdown rats showed sPLA2-XIIA role in controlling both attention and working 
memory which might be causes of both ADHD and schizophrenia. 
Together, the above results show an important role of sPLA2-XIIA in lipid 
metabolism and cognition. We postulate, in view of our finding of a catalytically 
active full length 24kDa secretion-capable isoform with signal peptide, that 
sPLA2-XIIA may induce remodeling of opposing neural cell membranes to 
facilitate axon pathfinding and neural plasticity in the brain. The deficiency in 
decision making and its accuracy after sPLA2-XIIA knockdown could involve 
alterations in dopamine or serotonin receptors (Puumala and Sirviö, 1998). AA 
and other polyunsaturated fatty acids (PUFA) affect dopaminergic and 
serotoninergic neurotransmission in the frontal cortex (de la Presa Owens and 
Innis, 1999). Studies have shown that pigs on a diet deficient in AA and DHA (de 
la Presa Owens and Innis, 1999) or rats deficient in n-3 PUFA contain 
significantly decreased level of dopamine in the frontal cortex (Zimmer et al., 
1999). Hypodopaminergic states could cause impaired attention, motivation and 
emotion as observed in ADHD (Puumala and Sirviö, 1998). There is also 
evidence that dysfunction of the cerebello-thalamo-striatal-prefrontal circuit, 







control/inhibition and executive function deficits (Biederman, 2005). However, 






























4.1 Signal Peptide Ablation 
 The lack of a functional signal peptide in simple functional systems i.e. 
cells and post-natal rats will present an interesting topic of study. Till date, the 
signal peptide is believed to assist sPLA2 in its secretion into extracellular spaces. 
However, its roles in these spaces are still not adequately defined. The usage of 
cloning techniques could provide more insights towards its role, in particular the 
physiological effects that could occur if sPLA2-XIIA are not secreted into 
extracellular spaces. 
 
4.2 Role of sPLA2 in Primary Neuronal Cultures  
 It would be enriching to characterize the role and distribution of sPLA2-
XIIA in primary neuronal cultures in order to better understand its role in axonal 
outgrowth. The pre- and post-synaptic locations could be critical in the 
understanding of its function as well as its underlying mechanisms. 
 
4.3 Significance of Changes in Lipid Profiles 
 The changes in lipid profiles are postulated to result in dopamine depletion 
and consequently, memory or attention and behaviour impairments. However, 
the effects of each individual lipid species that showed changes between normal 
and sPLA2-XIIA knockdown rats are not fully elucidated. Further studies could be 
done to confirm the hypothesis for mechanisms which would then significantly 
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